In this regard, results from the British Society for Rheumatology Biologics Register showed that the risk of myocardial infarction was markedly reduced in RA patients who responded to anti-TNF-alpha therapy by 6 months compared with nonresponders [11]. This evidence concerns the gene TNF and myocardial infarction.